Phase 1 randomized, double-blind, placebo controlled, single centre study of of GLPG3221 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2017
At a glance
- Drugs GLPG-3221 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 28 Nov 2017 New trial record
- 21 Nov 2017 According to a Galapagos NV media release, Topline results are expected to be disclosed at a future medical conference.